Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
LONDON - A British physician has received international recognition for implementing a light-activated therapy that significantly reduced surgical infections at National Health Service hospitals, according to a press release issued Monday.
Dr. Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, was awarded the President’s Award at the 19th World Congress of the International Photodynamic Association in Shanghai.
Bond was honored for introducing Steriwave photodisinfection, a nasal therapy developed by Ondine Biomedical Inc. (AIM:OBI), at Pinderfields and Pontefract hospitals. The treatment was used before knee and hip replacement surgeries and achieved a 71% reduction in surgical site infections over a six-month period.
The therapy involves applying a photosensitive agent to the nostrils followed by illumination with a specific wavelength of red light, which destroys pathogens in minutes without contributing to antimicrobial resistance.
"Dr. Bond and his team at Mid Yorks were the first to operationalize photodisinfection within the NHS," said Dr. Colin Hopper, President of the International Photodynamic Association, in the statement.
The International Photodynamic Association is a global organization focused on advancing research and clinical applications of photodynamic technologies across medical fields.
The Mid Yorkshire Teaching NHS Trust implementation represents the first use of this specific photodisinfection approach within the NHS system, according to the company’s announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.